Vivimed Labs Ltd Hits Lower Circuit Amid Heavy Selling Pressure

Market Performance and Price Action

On 16 Feb 2026, Vivimed Labs Ltd’s share price plunged to ₹7.04 intraday, touching the lower circuit band of 5%, before settling marginally higher at ₹7.08. This represented a maximum daily loss of ₹0.33 per share, or 4.45%, signalling a strong bearish sentiment. The stock’s high for the day was ₹7.59, indicating a significant intraday range of ₹0.55, but the overwhelming selling pressure prevented any meaningful recovery.

The total traded volume stood at 1.01762 lakh shares, with a turnover of approximately ₹0.073 crore, underscoring moderate liquidity for a micro-cap stock. Despite this, the delivery volume on 13 Feb was 3.42 lakh shares, which has since dropped by 44.71% compared to the five-day average, highlighting a sharp fall in investor participation.

Contextualising the Decline

Vivimed Labs is currently trading close to its 52-week low, just 4.95% above the bottom price of ₹6.72. The stock has reversed its short-term uptrend after two consecutive days of gains, signalling a potential shift in market sentiment. It has also slipped below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — which typically indicates sustained weakness and a bearish trend.

In comparison, the Pharmaceuticals & Drugs sector recorded a positive return of 0.73% on the same day, while the Sensex was nearly flat with a 0.06% gain. This divergence emphasises the stock’s underperformance relative to its peers and the broader market.

Investor Sentiment and Ratings

MarketsMOJO’s latest assessment downgraded Vivimed Labs Ltd from a ‘Sell’ to a ‘Strong Sell’ rating on 5 Feb 2026, reflecting deteriorating fundamentals and weak market outlook. The company’s Mojo Score stands at a low 24.0, with a Market Cap Grade of 4, categorising it firmly as a micro-cap stock with elevated risk factors.

The downgrade and negative sentiment have likely contributed to the panic selling observed, as investors rush to exit positions amid uncertainty. The unfilled supply of shares at lower price levels has exacerbated the downward pressure, triggering the circuit breaker to prevent further freefall.

Technical Indicators and Trend Analysis

The stock’s failure to hold above its short and long-term moving averages signals a bearish technical setup. The 5-day moving average, often used to gauge immediate momentum, is now above the current price, indicating selling dominance. Similarly, the 50-day and 200-day averages, which reflect medium and long-term trends, have also been breached, confirming a downtrend.

Such technical deterioration often leads to increased volatility and heightened risk of further declines, especially in micro-cap stocks where liquidity constraints can amplify price swings. The sharp drop in delivery volumes further suggests that long-term holders are either exiting or withholding fresh buying interest, compounding the negative outlook.

Sectoral and Market Implications

Vivimed Labs operates within the Pharmaceuticals & Drugs industry, a sector that has generally shown resilience amid market fluctuations. However, the stock’s underperformance relative to its sector peers raises questions about company-specific challenges, possibly related to earnings, regulatory issues, or operational setbacks.

Given the micro-cap status with a market capitalisation of ₹62 crore, the stock is more susceptible to speculative trading and sudden sentiment shifts. Investors should be cautious, as the current strong sell rating and technical weakness suggest limited near-term upside.

Outlook and Investor Considerations

With the stock hitting its lower circuit limit, investors face a critical juncture. The unfilled supply of shares at lower prices indicates persistent selling interest, which may continue to weigh on the stock until fresh positive triggers emerge. The current market environment, combined with the downgrade to a Strong Sell rating, advises caution for both existing shareholders and potential buyers.

Investors should closely monitor upcoming corporate announcements, quarterly results, and sectoral developments to reassess the stock’s prospects. Given the micro-cap nature and volatile price action, risk management and position sizing are paramount.

In summary, Vivimed Labs Ltd’s recent price action reflects a confluence of negative factors — technical weakness, reduced investor participation, and a deteriorating fundamental outlook — culminating in a sharp decline and circuit breaker intervention. Until these headwinds abate, the stock is likely to remain under pressure.

Summary of Key Metrics:

• Closing Price (16 Feb 2026): ₹7.08
• Intraday Low: ₹7.04 (Lower Circuit)
• Maximum Daily Loss: 4.45% (₹0.33)
• Total Traded Volume: 1.01762 lakh shares
• Turnover: ₹0.073 crore
• Mojo Score: 24.0 (Strong Sell)
• Market Cap: ₹62 crore (Micro Cap)
• Distance from 52-Week Low: 4.95%
• Underperformance vs Sector: -5.52%
• Underperformance vs Sensex: -4.51%

Final Thoughts

Vivimed Labs Ltd’s plunge to the lower circuit limit is a stark reminder of the risks inherent in micro-cap stocks, especially those facing fundamental and technical challenges. While the Pharmaceuticals & Drugs sector remains broadly stable, company-specific issues have triggered a wave of panic selling, reflected in the sharp price drop and diminished investor interest. Market participants should exercise prudence and consider alternative investment opportunities until the stock demonstrates signs of recovery.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →